<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neurologic complications of cancer treatment with molecularly targeted and biologic agents</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neurologic complications of cancer treatment with molecularly targeted and biologic agents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neurologic complications of cancer treatment with molecularly targeted and biologic agents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eudocia Quant Lee, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Y Wen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reed E Drews, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neurologic complications of anticancer therapy may result from direct toxic effects on the nervous system, or indirectly from drug-induced metabolic derangements or cerebrovascular disorders, or, in the case of <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, autoimmune disorders. Their recognition is important because of potential confusion with metastatic disease, paraneoplastic syndromes or comorbid neurologic disorders that do not require dose reduction or discontinuation. If the neurologic disorder is caused by the chemotherapy, discontinuation of the offending agent may prevent irreversible injury.</p><p>Here we discuss the neurologic complications associated with molecularly targeted and biologic agents, including both biologic response modifiers and therapeutic monoclonal antibodies. The neurologic complications associated with conventional cytotoxic chemotherapy agents and chimeric antigen receptor (CAR) T-cell therapies are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy"</a> and  <a class="medical medical_review" href="/z/d/html/2826.html" rel="external">"Overview of neurologic complications of platinum-based chemotherapy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">BIOLOGIC RESPONSE MODIFIERS</span><span class="headingEndMark"> — </span>Until recently, biologic response modifiers were often used in combination with conventional chemotherapeutic agents (biochemotherapy) for a number of cancers. However, these regimens have largely been replaced with newer targeted agents and immunotherapies in most cancers.</p><p class="headingAnchor" id="H3"><span class="h2">Interferon</span><span class="headingEndMark"> — </span>Interferon alfa (IFNa) is occasionally used to treat hairy cell leukemia, Kaposi sarcoma, melanoma, and chronic myeloid leukemia (CML). IFNa is associated with a variety of substantial toxicities, which may limit the ability to deliver a full course of therapy [<a href="#rid1">1</a>]. Frequent systemic toxicities include flu-like symptoms (myalgias, nausea, vomiting, arthralgias, fever, chills, and headache) and depression. The flu-like symptoms tend to be worse at the onset of therapy and usually improve with time.</p><p>Neurotoxicity tends to be dose-related. It is generally mild when low doses of IFNa are used, as in the adjuvant setting for patients with malignant melanoma. In a detailed evaluation of 37 such patients treated with IFNa, the most frequent neurotoxicity was tremor, observed in eight cases (22 percent) [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/7615.html" rel="external">"Adjuvant and neoadjuvant therapy for cutaneous melanoma", section on 'Adjuvant therapies not commonly used'</a>.)</p><p>At higher doses, such as those used for patients with advanced melanoma, IFNa can cause confusion, lethargy, hallucinations, and seizures [<a href="#rid3">3,4</a>]. Although these effects are usually reversible, a permanent dementia or persistent vegetative state may result [<a href="#rid4">4</a>].</p><p>More commonly, patients develop a depressive syndrome over weeks to months. Neuropsychiatric symptoms are usually mild to moderate and typically resolve within two to three weeks of IFN discontinuation [<a href="#rid5">5</a>]. Cognitive impairments involving memory, processing speed, and executive functioning have also been reported in some studies of cancer patients receiving IFNa [<a href="#rid6">6,7</a>] but not in others [<a href="#rid2">2,8</a>].</p><p>Rarely, IFNa has been associated with oculomotor palsy, sensorimotor neuropathy [<a href="#rid9">9</a>], myasthenia gravis [<a href="#rid10">10</a>], brachial plexopathy, an action tremor [<a href="#rid11">11</a>], and polyradiculopathy [<a href="#rid12">12</a>].</p><p>There were two available preparations of IFNa (2a and 2b), but <a class="drug drug_general" data-topicid="8563" href="/z/d/drug information/8563.html" rel="external">interferon alfa-2b</a> has been discontinued worldwide.</p><p>The side effect profile of pegylated preparations of IFNa 2a, which have a longer half-life, are similar to those observed with standard IFNa-2a except that in some studies, neutropenia and thrombocytopenia are slightly more severe [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/3661.html" rel="external">"Pegylated interferon for treatment of chronic hepatitis B virus infection", section on 'Adverse reactions'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Interleukin 2</span><span class="headingEndMark"> — </span>Interleukin 2 (IL-2) has been used both alone and in several biochemotherapy combinations, both with and without IFN, for a number of cancers, particularly renal cell carcinoma and melanoma. (See  <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma"</a> and  <a class="medical medical_review" href="/z/d/html/15407.html" rel="external">"Interleukin 2 and experimental immunotherapy approaches for advanced melanoma"</a> and  <a class="medical medical_review" href="/z/d/html/15407.html" rel="external">"Interleukin 2 and experimental immunotherapy approaches for advanced melanoma", section on 'Toxicity'</a>.)</p><p>Toxicity is dose-dependent. Neuropsychiatric complications, which occur in up to 30 to 50 percent of patients, include cognitive changes, delusions, hallucinations, and depression [<a href="#rid14">14</a>]. Confusion may be a dose-limiting effect of high-dose IL-2 regimens, but it is rarely seen with combination biochemotherapy regimens [<a href="#rid15">15</a>]. Symptoms typically resolve upon termination of treatment [<a href="#rid16">16</a>].</p><p>Less commonly, transient focal neurologic deficits [<a href="#rid17">17</a>], acute leukoencephalopathy, carpal tunnel syndrome, myositis [<a href="#rid18">18</a>], myasthenia gravis [<a href="#rid19">19</a>], and brachial neuritis [<a href="#rid20">20</a>] have been reported with IL-2. Administration of IL-2 directly into the tumor bed (with lymphokine-activated killer [LAK] cells) for the treatment of gliomas can cause significant cerebral edema, and neurotoxicity appears to be dose-limiting [<a href="#rid21">21,22</a>].</p><p>One case of grade 5 neurotoxicity has been reported in a patient treated with IL-2 and granulocyte macrophage colony-stimulating factor (GM-CSF). This patient experienced a fatal cerebral hemorrhage associated with thrombocytopenia, leading the authors to recommend extreme caution in using these agents together [<a href="#rid23">23</a>]. Others have not reported excessive neurotoxic effects in patients treated with both agents [<a href="#rid24">24,25</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Tumor necrosis factor</span><span class="headingEndMark"> — </span>Systemic administration of tumor necrosis factor-alpha (TNF-a) is limited by toxicity; neurologically, these effects include encephalopathy, transient aphasia, or other focal deficits [<a href="#rid26">26</a>]. As a result, the use of TNF-a in patients with cancer is limited to isolated limb perfusion for patients with advanced sarcoma or melanoma. Isolated limb perfusion with TNF-a is associated with a mild sensory neuropathy that typically begins two to three weeks after perfusion and generally abates after eight weeks [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/7608.html" rel="external">"Cutaneous melanoma: In-transit metastases"</a> and  <a class="medical medical_review" href="/z/d/html/7607.html" rel="external">"Cutaneous melanoma: Management of local recurrence"</a> and  <a class="medical medical_review" href="/z/d/html/7732.html" rel="external">"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">MONOCLONAL ANTIBODIES AND ANTIBODY-DRUG CONJUGATES</span></p><p class="headingAnchor" id="H1068860363"><span class="h2">Alemtuzumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">Alemtuzumab</a> is a humanized monoclonal antibody that targets CD52 and is approved for the treatment of B-cell chronic lymphocytic leukemia. Similar to <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, progressive multifocal leukoencephalopathy (PML) has been reported in patients treated with this agent [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H822857413"><span class="h2">Bevacizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">Bevacizumab</a> is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) used in the treatment of a variety of cancers. Several clinical trials of bevacizumab or one of its biosimilars combined with chemotherapy suggest a significant increase in the risk of serious arterial thromboembolic events (including transient ischemic attack, cerebrovascular accident, and myocardial infarction). (See  <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Bevacizumab and aflibercept'</a>.)</p><p>Reversible posterior leukoencephalopathy syndrome (RPLS) occurs in less than 0.1 percent of patients treated with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> or one of its biosimilars. Symptoms can include headache, seizure, lethargy, confusion, blindness, and other visual and neurologic disturbances. RPLS may be associated with mild to severe hypertension. The onset may occur from 16 hours to one year after initiation of therapy. Symptoms usually resolve with discontinuation of bevacizumab and control of any associated hypertension. (See  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Reversible posterior leukoencephalopathy and brain capillary leak syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/4835.html" rel="external">"Reversible posterior leukoencephalopathy syndrome"</a>.)</p><p><a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">Bevacizumab</a> increases the risk for bleeding, and concerns have been raised about a potential increase in the risk of intracerebral hemorrhage in patients treated with bevacizumab who have brain metastases or primary brain tumors. However, the available data suggest that rates of serious hemorrhage are low. Patients with a history of treated nonhemorrhagic brain metastases probably should not be excluded from systemic therapy with bevacizumab or other angiogenic therapies as long as they are not on concurrent anticoagulation. (See  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Intracranial bleeding'</a>.)</p><p>The decision to use <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> in an anticoagulated patient with a recurrent primary brain tumor is more complex and must be based upon a careful assessment of the risk to benefit ratio. This subject is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5205.html" rel="external">"Management of recurrent high-grade gliomas", section on 'Side effects'</a>.)</p><p>Rarely, severe optic neuropathy has been reported in brain tumor patients after <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> treatment [<a href="#rid29">29</a>]. In a case series of six patients, all had previously received standard chemoradiation, with radiation doses to the optic apparatus that were limited to those generally considered within tolerance levels.</p><p class="headingAnchor" id="H1412276323"><span class="h2">Cetuximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">Cetuximab</a> is a chimeric mouse-human antibody against epidermal growth factor that is used in the treatment of head and neck cancer as well as colorectal cancer. In a study of 420 patients with advanced colorectal cancer who received cetuximab monotherapy, 26 percent developed headaches [<a href="#rid30">30</a>]. Patients on cetuximab may develop symptomatic hypomagnesemia, which may lead to severe fatigue, cramps, and somnolence. (See  <a class="medical medical_review" href="/z/d/html/114914.html" rel="external">"Nephrotoxicity of molecularly targeted agents and immunotherapy", section on 'EGFR inhibitors'</a>.)</p><p>Cases of aseptic meningitis have also been reported in association with <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> [<a href="#rid31">31-33</a>].</p><p class="headingAnchor" id="H4146606100"><span class="h2">Brentuximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16806" href="/z/d/drug information/16806.html" rel="external">Brentuximab vedotin</a> is a CD30-directed antibody-drug conjugate that is used for treatment of certain CD30-positive lymphomas. (See  <a class="medical medical_review" href="/z/d/html/4765.html" rel="external">"Treatment of relapsed or refractory classic Hodgkin lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4742.html" rel="external">"Treatment of relapsed or refractory peripheral T cell lymphoma", section on 'Brentuximab'</a>.)</p><p>In clinical trials, 36 to 69 percent of patients treated with brentuximab developed a peripheral neuropathy of any grade; approximately 4 to 14 percent had severe (grade 3 or 4  (<a class="graphic graphic_table graphicRef78736" href="/z/d/graphic/78736.html" rel="external">table 1</a>)) neuropathy [<a href="#rid34">34-39</a>]. The peripheral neuropathy was mainly sensory and cumulative, but motor neuropathy was also reported.</p><p>Neuropathy is reversible in approximately two-thirds of patients with long-term follow-up. In the ESCHELON-1 trial of 1334 patients with Hodgkin lymphoma, 72 percent of patients who developed neuropathy of any grade had complete resolution with median follow-up of 61 months [<a href="#rid40">40</a>]. Fourteen percent had partial resolution, and 14 percent had ongoing neuropathy without improvement. The median times to partial and complete resolution were 2.9 and 6.6 months, respectively.</p><p>The US Food and Drug Administration (FDA)-approved manufacturer's labeling recommends that dosing of brentuximab be held for new or worsening grade 2 or 3  (<a class="graphic graphic_table graphicRef78736" href="/z/d/graphic/78736.html" rel="external">table 1</a>) neuropathy, held until improvement to grade 1, then restarted at a lower dose; the drug should be discontinued for grade 4 neuropathy.</p><p>Rare reports of PML prompted the FDA to add a boxed warning regarding this complication in January 2012. In addition, there is a single report documenting 11 cases of inflammatory demyelinating polyradiculoneuropathy consistent with Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy in patients treated with brentuximab [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/5137.html" rel="external">"Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5264.html" rel="external">"Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2585632060"><span class="h2">Bispecific T cell engagers</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blinatumomab</strong> – <a class="drug drug_general" data-topicid="98582" href="/z/d/drug information/98582.html" rel="external">Blinatumomab</a> is a bispecific T cell engager monoclonal antibody directed at both CD19 on precursor B-cell acute lymphoblastic leukemia (ALL) tumor cells and CD3 on cytotoxic T cells that has activity in the treatment of Philadelphia chromosome (Ph)-negative relapsed or refractory B-cell precursor ALL. (See  <a class="medical medical_review" href="/z/d/html/4518.html" rel="external">"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults", section on 'Blinatumomab'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="98582" href="/z/d/drug information/98582.html" rel="external">Blinatumomab</a> is administered by continuous intravenous infusion over four weeks followed by a two-week treatment-free interval. Patients are hospitalized around the time of infusion initiation to monitor for signs and symptoms of cytokine release syndrome and neuropsychiatric toxicities, including seizures. (See  <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Blinatumomab'</a>.)</p><p></p><p class="bulletIndent1">Neurotoxicity is commonly observed after <a class="drug drug_general" data-topicid="98582" href="/z/d/drug information/98582.html" rel="external">blinatumomab</a>. A wide range of symptoms have been described, ranging from headache and tremor to more severe encephalopathy, referred to as immune effector cell-associated neurotoxicity syndrome (ICANS). Prescribing information for blinatumomab contains recommendations for dose reduction and/or discontinuation based upon the neurotoxicity severity. Recognition and treatment of ICANS are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/129618.html" rel="external">"Immune effector cell-associated neurotoxicity syndrome (ICANS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Teclistamab</strong> – <a class="drug drug_general" data-topicid="139997" href="/z/d/drug information/139997.html" rel="external">Teclistamab</a> is a bispecific T cell engager monoclonal antibody directed at both B cell maturation antigen (BCMA) on multiple myeloma tumor cells and CD3 on the patient’s T-cells. It is approved in the United States for treatment of refractory multiple myeloma. (See  <a class="medical medical_review" href="/z/d/html/131449.html" rel="external">"Multiple myeloma: Treatment of third or later relapse", section on 'Bispecific antibodies'</a>.)</p><p></p><p class="bulletIndent1">Prescribing information carries warnings for ICANS, which is seen in over 50 percent of patients. Recognition and treatment of ICANS are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/129618.html" rel="external">"Immune effector cell-associated neurotoxicity syndrome (ICANS)"</a>.)</p><p></p><p class="headingAnchor" id="H1761406425"><span class="h2">Enfortumab vedotin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="126407" href="/z/d/drug information/126407.html" rel="external">Enfortumab vedotin</a> is a nectin-4-directed monoclonal antibody microtubule inhibitor drug conjugate that is approved for metastatic refractory urothelial cancer. (See  <a class="medical medical_review" href="/z/d/html/3000.html" rel="external">"Treatment of metastatic urothelial carcinoma of the bladder and urinary tract"</a>.)</p><p>In the initial clinical trial of 125 patients treated with <a class="drug drug_general" data-topicid="126407" href="/z/d/drug information/126407.html" rel="external">enfortumab vedotin</a>, peripheral sensory neuropathy developed in 50 (40 percent), but it was severe (grade 3 or 4) in only two (2 percent) [<a href="#rid42">42</a>]. A similar frequency was reported in an expanded set of 310 patients treated with the drug (50 percent any grade, 2 percent grade 3) [<a href="#rid43">43</a>]. The median time to onset of grade 2 or worse neuropathy was 3.8 months. Of the patients who developed neuropathy, at the time of the last evaluation, 19 percent had resolved completely, and 26 percent had partial improvement. The prescribing information for enfortumab suggests withholding the drug for grade 2 or worse symptoms.</p><p class="headingAnchor" id="H3198034466"><span class="h2">Polatuzumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="121575" href="/z/d/drug information/121575.html" rel="external">Polatuzumab vedotin</a> is an antibody-drug conjugate containing the antimicrotubule agent monomethyl auristatin E that is approved in combination with <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">bendamustine</a> and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> for treatment of relapsed or refractory diffuse large B-cell lymphoma. (See  <a class="medical medical_review" href="/z/d/html/132087.html" rel="external">"Diffuse large B cell lymphoma (DLBCL): Second or later relapse or patients who are medically unfit", section on 'Polatuzumab/bendamustine/rituximab'</a>.)</p><p>Polatuzumab can cause a predominantly sensory peripheral neuropathy, which is usually mild, but can be severe [<a href="#rid44">44</a>]. It can occur as early as the first cycle of therapy, and is cumulative. In one study of 173 patients treated with polatuzumab plus <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">bendamustine</a> and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, 40 percent reported new or worsening neuropathy, which was grade 1 in 26 percent, grade 2 in 12 percent, and grade 3 in 2.3 percent [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H2394536848"><span class="h2">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> is a humanized monoclonal antibody directed against the CD20 antigen that is found on the surface of normal and malignant B lymphocytes. It is used for the treatment of low-grade or follicular B-cell lymphoma, as well as other disorders where B lymphocytes are involved in disease pathogenesis. Neurologic complications are uncommon, but some patients complain of headaches, myalgias, dizziness [<a href="#rid46">46,47</a>], or paresthesias [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/z/d/html/4741.html" rel="external">"Initial treatment of stage I follicular lymphoma"</a>.)</p><p>Rare cases of PML have been reported in patients being treated with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid49">49</a>]. In a review of 57 patients who developed PML after rituximab, all patients had received prior therapies with alkylating agents, corticosteroids, purine analogs, or drugs to prevent allogeneic stem cell or solid organ graft rejection. (See  <a class="medical medical_review" href="/z/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p>In addition, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> has been associated with RPLS [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/4835.html" rel="external">"Reversible posterior leukoencephalopathy syndrome"</a>.)</p><p>Intrathecal (IT) <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> is also reasonably well-tolerated. In a phase I study, none of the five patients treated at the maximum tolerated IT dose of 25 mg exhibited toxicity. The dose-limiting toxicity at 50 mg was grade 3 hypertension, with one patient experiencing transient diplopia, nausea, and vomiting in the setting of hypertension [<a href="#rid51">51</a>]. However, acute-onset, painful lumbosacral paresthesias have been reported in patients treated with IT rituximab 25 mg via lumbar puncture, occurring immediately after administration of the drug and resolving completely within a few hours [<a href="#rid51">51,52</a>]. There were no neurologic deficits associated with the events or on follow-up.</p><p class="headingAnchor" id="H680403253"><span class="h2">Tisotumab vedotin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="132755" href="/z/d/drug information/132755.html" rel="external">Tisotumab vedotin</a> is a tissue factor-directed antibody and microtubule inhibitor drug-conjugate approved for use for those with recurrent or metastatic cervical cancer with disease progression on, or after, chemotherapy. (See  <a class="medical medical_review" href="/z/d/html/3185.html" rel="external">"Management of recurrent or metastatic cervical cancer", section on 'Second-line therapy'</a>.)</p><p>Across clinical trials, neurologic toxicity has occurred in 42 percent of patients with cervical cancer treated with <a class="drug drug_general" data-topicid="132755" href="/z/d/drug information/132755.html" rel="external">tisotumab vedotin</a>; 8 percent experienced grade 3 peripheral neuropathy [<a href="#rid53">53</a>]. Adverse reactions have included peripheral neuropathy (20 percent), which can be both sensory and motor, muscular weakness (3 percent), and demyelinating peripheral polyneuropathy (1 percent). The median time to onset was 2.4 months (range 0 to 11.3 months). Symptoms improved in many patients with discontinuation of therapy. Dose reduction guidelines for neuropathy are included in the companion drug information for tisotumab vedotin.</p><p class="headingAnchor" id="H13"><span class="h2">Tositumomab radioconjugate</span><span class="headingEndMark"> — </span>Tositumomab radioconjugate (Iodine-131 tositumomab) is one of several anti-CD-20 radioimmunoconjugates used in the treatment of indolent non-Hodgkin lymphoma. These agents deliver targeted radiotherapy to tumor-bearing areas. A minority of treated patients experience headache or myalgias during treatment [<a href="#rid54">54,55</a>]. (See  <a class="medical medical_review" href="/z/d/html/4755.html" rel="external">"Treatment of relapsed or refractory follicular lymphoma", section on 'Radioimmunotherapy'</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Trastuzumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">Trastuzumab</a> is a humanized anti-HER2 monoclonal antibody that is used either alone or in combination with cytotoxic agents for the treatment of HER2-overexpressing breast cancer in the metastatic and adjuvant settings. (See  <a class="medical medical_review" href="/z/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">"Systemic treatment for HER2-positive metastatic breast cancer"</a>.)</p><p>A few patients experience headaches, dizziness, and insomnia after infusion of the antibody [<a href="#rid56">56</a>]. Paresthesias and peripheral neuropathy are even less common.</p><p class="headingAnchor" id="H351181285"><span class="h3">Ado-trastuzumab emtansine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="88427" href="/z/d/drug information/88427.html" rel="external">Ado-trastuzumab emtansine</a> (T-DM1) is an antibody-drug conjugate that incorporates <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a> with the cytotoxic microtubule inhibitor DM1. It is approved for advanced breast cancer in patients previously exposed to trastuzumab and taxanes. (See  <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">"Systemic treatment for HER2-positive metastatic breast cancer", section on 'Treatment-free interval of less than six months'</a>.)</p><p>Peripheral neuropathy, mainly grade 1 and predominantly sensory, has been reported in 21 to 22 percent of treated patients in clinical trials; it was grade 3 or worse in 1.5 to 2.2 percent [<a href="#rid57">57</a>]. The drug should be temporarily discontinued for grade 3 or 4 toxicity until resolution to ≤grade 2.</p><p>T-DM1 may be associated with an increase in the risk of central nervous system radiation necrosis and/or cerebral edema from brain metastases treated with stereotactic radiosurgery (SRS). In one retrospective review of 12 patients, the incidence of radiation necrosis was 50 percent for patients who received T-DM1 during SRS and 28.6 percent for patients who discontinued T-DM1 before SRS [<a href="#rid58">58</a>]. In another series of four patients, T-DM1 was associated with significantly increased cerebral edema at sites of prior SRS as evidenced by brain magnetic resonance imaging (MRI) as well as neurologic findings [<a href="#rid59">59</a>]. The time between SRS and T-DM1 infusion ranged from 3 to 449 days.</p><p class="headingAnchor" id="H3661331755"><span class="h1">IMMUNE CHECKPOINT INHIBITORS</span><span class="headingEndMark"> — </span>Immune checkpoint inhibitors are used in the treatment of multiple cancers; these agents work by blocking the interaction between immune checkpoint proteins on the surface of cytotoxic T cells such as cytotoxic T-lymphocyte-associated-4 (CTLA-4) and programmed cell death protein 1 (PD-1) and their ligands, CD80/CD86 and programmed death-ligand 1 (PD-L1), respectively. <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">Pembrolizumab</a>, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>, and <a class="drug drug_general" data-topicid="119172" href="/z/d/drug information/119172.html" rel="external">cemiplimab</a> are monoclonal antibodies against PD-1, whereas <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a>, <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">avelumab</a>, and <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a> are monoclonal antibodies against PD-L1. <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">Ipilimumab</a> is a monoclonal antibody directed against CTLA-4 and is used alone or in combination with nivolumab.</p><p>Checkpoint inhibitors break down tolerance to the tumor-associated antigens, and this may result in decreased tolerance to self-antigens, leading to immune-related adverse effects (irAEs). The overall incidence of neurologic irAEs in patients treated with ICIs is low overall, with the most common being headache and peripheral sensory neuropathy. More serious neurologic irAEs occur infrequently including motor neuropathy, Guillain-Barré syndrome, myasthenia gravis, encephalitis, aseptic meningitis, transverse myelitis, and lymphocytic hypophysitis causing hypopituitarism. These toxicities are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Neurologic'</a> and  <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Hypophysitis'</a>.)</p><p class="headingAnchor" id="H1741760009"><span class="h1">CAR-T CELL THERAPY</span><span class="headingEndMark"> — </span>In CAR-T cell therapy, the patient's T cells are collected from blood and modified to express a chimeric antigen receptor (CAR) specific for a tumor antigen, followed by <em>ex vivo</em> expansion and then re-infusion back to the patient. Multiple CAR-T cell immunotherapies are approved by the US Food and Drug Administration to treat certain types of relapsed or refractory B-cell hematologic malignancies. (See  <a class="medical medical_review" href="/z/d/html/4518.html" rel="external">"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults", section on 'CAR-T'</a> and  <a class="medical medical_review" href="/z/d/html/132087.html" rel="external">"Diffuse large B cell lymphoma (DLBCL): Second or later relapse or patients who are medically unfit", section on 'Chimeric antigen receptor T cell therapy'</a> and  <a class="medical medical_review" href="/z/d/html/131449.html" rel="external">"Multiple myeloma: Treatment of third or later relapse", section on 'Chimeric antigen receptor T cells'</a>.)</p><p>Neurotoxicity is a common toxicity observed after CAR-T cell therapy. A wide range of symptoms have been described, ranging from headaches to encephalopathy, also known as immune effector cell-associated neurotoxicity syndrome (ICANS). In addition to ICANS, other neurologic toxicities have also been observed with certain products, including transverse myelitis, Guillain-Barre syndrome, cranial neuropathies, and delayed-onset parkinsonism. ICANS and other neurologic toxicities are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/129618.html" rel="external">"Immune effector cell-associated neurotoxicity syndrome (ICANS)"</a>.)</p><p class="headingAnchor" id="H1731182650"><span class="h1">NTRK INHIBITORS</span></p><p class="headingAnchor" id="H3840707296"><span class="h2">Larotrectinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">Larotrectinib</a>, an orally active, highly selective inhibitor of the neurotrophic tyrosine receptor kinase (<em>NTRK</em>) gene, is approved for a variety of solid tumors that have <em>NTRK</em> gene fusions. (See  <a class="medical medical_review" href="/z/d/html/3382.html" rel="external">"Malignant salivary gland tumors: Treatment of recurrent and metastatic disease", section on 'Secretory (NTRK gene fusion positive)'</a> and  <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">"Overview of the initial treatment of metastatic soft tissue sarcoma", section on 'NTRK gene fusion-positive tumors'</a>.)</p><p>Neurologic events are common in patients treated with <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">larotrectinib</a>, but most are mild. Among 176 patients who received the drug, neurologic adverse events of any grade occurred in 53 percent, including grade 3 and 4 events in 6 and 0.6 percent, respectively [<a href="#rid60">60</a>]. The majority occurred within the first three months of treatment. Reactions included dizziness, gait disturbance, delirium, memory impairment, and tremor; the grade 3 and 4 events included delirium, dysarthria, dizziness, gait disturbance, paresthesias, and encephalopathy.</p><p>Prescribing information for <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">larotrectinib</a> suggests withholding or permanently discontinuing the drug based on severity; if the drug is withheld, the dose should be reduced when treatment is resumed.</p><p class="headingAnchor" id="H1889607397"><span class="h2">Entrectinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">Entrectinib</a> is an oral NTRK/ROS inhibitor approved for solid tumors with <em>NTRK</em> gene fusions as well as <em>ROS1</em>-positive metastatic non-small cell lung cancer. A variety of neurologic events have also been described with entrectinib, including cognitive impairment, mood disorders, dizziness, and sleep disturbances. In 355 patients treated with entrectinib across clinical trials, 27 percent experienced cognitive impairment, although grade 3 events occurred in only 4.5 percent [<a href="#rid61">61</a>]. Prescribing information for entrectinib similarly suggests withholding or permanently discontinuing the drug based on severity; if the drug is withheld, the dose should be reduced when treatment is resumed.</p><p class="headingAnchor" id="H3148457276"><span class="h1">LORLATINIB</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="119539" href="/z/d/drug information/119539.html" rel="external">Lorlatinib</a> is a third-generation inhibitor of anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinases that is approved for <em>ALK</em> mutation-positive non-small cell lung cancer that is refractory to other ALK inhibitors. (See  <a class="medical medical_review" href="/z/d/html/4621.html" rel="external">"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer", section on 'Lorlatinib'</a>.)</p><p>An unusual pattern of neurotoxicity has been reported with this agent that appears to be unique compared with other ALK inhibitors. In a phase II trial of 276 patients who received <a class="drug drug_general" data-topicid="119539" href="/z/d/drug information/119539.html" rel="external">lorlatinib</a>, treatment-related adverse effects included cognitive dysfunction (more forgetful, difficulty with multitasking) in 49 (18 percent), mood effects (typically lability and/or irritability) in 41 (15 percent), speech disturbance (typically difficulty with word finding or slowing of speech) in 20 (7 percent), auditory hallucinations in five, and peripheral neuropathy in 83 (30 percent) [<a href="#rid62">62</a>]. Central nervous system effects of any cause were reported in 107 of the 276 patients overall (39 percent), and they were generally mild (grade 1 or 2) in severity, transient, dose dependent, intermittent, and reversible after dose reduction. The prescribing information for lorlatinib recommends withholding the drug for grade 2 or 3 central nervous system effects, resuming after resolution to grade ≤1 toxicity with a reduced dose, and permanent discontinuation for any grade 4 event.</p><p class="headingAnchor" id="H3037299665"><span class="h1">ORAL SMALL MOLECULE TYROSINE KINASE INHIBITORS</span></p><p class="headingAnchor" id="H3866846478"><span class="h2">Dasatinib, imatinib, and avapritinib</span><span class="headingEndMark"> — </span>Some of the orally available small molecule tyrosine kinase inhibitors targeting Bcr-Abl and other tyrosine kinases, such as platelet-derived growth factor receptor (PDGFR; eg, <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">dasatinib</a>, <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a>, <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">avapritinib</a>), have been associated with central nervous system toxicities, including dizziness, insomnia, mood disorders (especially depression), and dysgeusia, most of which are low grade. One of these drugs, avapritinib, an inhibitor of exon 18 mutations in platelet-derived growth factor receptor alfa (<em>PDGFRA</em>), has also been associated with a high frequency of cognitive impairment (48 percent, with 5 percent grade 3 or 4) and with intracranial hemorrhage in 1 to 3 percent of treated patients, either of which might necessitate withholding or discontinuing the drug [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H528070323"><span class="h2">Rare causes of neurotoxicity</span></p><p class="headingAnchor" id="H4259299491"><span class="h3">Ibrutinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">Ibrutinib</a> is a small molecule inhibitor of Bruton tyrosine kinase that is approved for treatment of mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease. Rarely, fatal bleeding events including intracranial hemorrhages have occurred. Rare cases of opportunistic infections such as progressive multifocal leukoencephalopathy and central nervous system aspergillosis have also been reported [<a href="#rid64">64-66</a>].</p><p class="headingAnchor" id="H3717908502"><span class="h3">Ivosidenib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">Ivosidenib</a> is a small molecule inhibitor of isocitrate dehydrogenase 1 (IDH1) that is approved for treatment of relapsed or refractory acute myeloid leukemia with a susceptible <em>IDH1</em> mutation. Rare cases of Guillain-Barré syndrome are reported (2 of 258 patients [&lt;1 percent] in one study [<a href="#rid67">67</a>]). However, this could represent a chance association. (See  <a class="medical medical_review" href="/z/d/html/4540.html" rel="external">"Treatment of relapsed or refractory acute myeloid leukemia", section on 'Remission re-induction'</a> and  <a class="medical medical_review" href="/z/d/html/5137.html" rel="external">"Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H217865135"><span class="h3">Selinexor</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="121843" href="/z/d/drug information/121843.html" rel="external">Selinexor</a> is a selective inhibitor of the nuclear export protein exportin 1 (XPO1) that is approved in combination with <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> for the treatment of multiply relapsed or refractory multiple myeloma. (See  <a class="medical medical_review" href="/z/d/html/131449.html" rel="external">"Multiple myeloma: Treatment of third or later relapse", section on 'Selinexor'</a>.)</p><p>Neurologic adverse reactions, including dizziness, syncope, depressed level of consciousness, and mental status changes (including delirium), have occurred in approximately 30 percent of patients treated with the drug; events were severe (grade 3 or worse) in 9 percent [<a href="#rid68">68</a>]. The median time to develop neurologic symptoms was 15 days. Fatigue is also a common side effect.</p><p class="headingAnchor" id="H723801697"><span class="h3">Axitinib, cabozantinib, lenvatinib, pazopanib, selpercatinib, sorafenib, sunitinib, and tivozanib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">Axitinib</a>, <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a>, <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a>, <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a>, <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">selpercatinib</a>, <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, and <a class="drug drug_general" data-topicid="131053" href="/z/d/drug information/131053.html" rel="external">tivozanib</a> are molecularly targeted agents that inhibit multiple tyrosine kinases including the vascular endothelial growth factor receptor (VEGFR) tyrosine kinase. An increased risk of hemorrhage, including rare central nervous system hemorrhages, arterial thromboembolic events, and reversible posterior leukoencephalopathy syndrome (RPLS) have been reported with agents that target VEGFR. (See  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Intracranial bleeding'</a>.)</p><p>A few cases of drug-induced toxic metabolic encephalopathy have been reported in patients receiving <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> for advanced hepatocellular cancer in the setting of cirrhosis [<a href="#rid69">69,70</a>].</p><p>A variety of types of neurotoxicity have been rarely reported with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>A single case report described a transient coma in a patient treated with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> for sarcoma, which resolved when treatment was discontinued and recurred with rechallenge [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">Sunitinib</a> can also cause hypothyroidism and may induce a hypothyroid coma [<a href="#rid72">72,73</a>]. (See  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Thyroid dysfunction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A reversible cognitive disorder characterized by confusion, hallucinations, or extrapyramidal symptoms has also been described in older adult patients with preexisting arteriosclerotic leukoencephalopathy [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RPLS is characterized by headaches, altered consciousness, visual disturbances, and seizures; hypertension is frequent but not invariable. Multiple case reports describe this complication in patients treated with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> [<a href="#rid75">75-79</a>] and other agents targeting angiogenesis. (See  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Reversible posterior leukoencephalopathy and brain capillary leak syndrome'</a>.)</p><p></p><p class="headingAnchor" id="H3295623767"><span class="h3">Vemurafenib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">Vemurafenib</a> is a potent inhibitor of the mutated <em>BRAF</em> gene, which is present in 40 to 60 percent of melanomas. There are isolated case reports of peripheral facial nerve palsy, which was bilateral in two patients [<a href="#rid80">80</a>].</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY</span><span class="headingEndMark"> — </span>Neurologic complications associated with anticancer treatments, including molecularly targeted and biologic agents, adversely impact quality of life and may limit further therapy. Some of the most common are summarized below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biologic response modifiers and neuropsychiatric complications</strong> – Interferons (IFN) and high-dose interleukin 2 (IL-2) are associated with neuropsychiatric complications. (See <a class="local">'Biologic response modifiers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PML</strong> – Rare cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients receiving a variety of agents, including <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>, brentuximab, <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>, and <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>. (See <a class="local">'Monoclonal antibodies and antibody-drug conjugates'</a> above and <a class="local">'Axitinib, cabozantinib, lenvatinib, pazopanib, selpercatinib, sorafenib, sunitinib, and tivozanib'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiangiogenic therapies and thromboembolic events</strong> – Patients receiving <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> alone or in combination with chemotherapy are at higher risk for thromboembolic events, including cerebrovascular accidents. Early recognition may help avoid permanent neurologic damage. (See <a class="local">'Bevacizumab'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Checkpoint inhibitors and immune-mediated adverse events</strong> – Although uncommon, a wide range of immune-mediated adverse events have been observed that affect the nervous system in patients treated with checkpoint inhibitors, including sensory and motor neuropathy, Guillain-Barré syndrome, myasthenia gravis, encephalitis, and aseptic meningitis. (See <a class="local">'Immune checkpoint inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CAR-T cells</strong> – CAR-T cell therapy carries a black box warning for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. This syndrome is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/129618.html" rel="external">"Immune effector cell-associated neurotoxicity syndrome (ICANS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bispecific T cell engagers</strong> – Approximately 50 percent of patients receiving <a class="drug drug_general" data-topicid="98582" href="/z/d/drug information/98582.html" rel="external">blinatumomab</a> or <a class="drug drug_general" data-topicid="139997" href="/z/d/drug information/139997.html" rel="external">teclistamab</a> develop neurologic or neuropsychiatric toxicities, and they may be severe. (See <a class="local">'Bispecific T cell engagers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TKIs and neurotoxicity</strong> – Some of the orally active small molecule tyrosine kinase inhibitors (TKIs) targeting Bcr-Abl and other tyrosine kinases, such as platelet-derived growth factor receptor (PDGFR), especially the exon 18 mutation platelet-derived growth factor receptor alfa (PDGFRA) inhibitor <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">avapritinib</a>, are associated with central nervous system toxicities, such as cognitive impairment or intracranial hemorrhage, which may necessitate withholding or discontinuing the drug. (See <a class="local">'Dasatinib, imatinib, and avapritinib'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TRK inhibitors</strong> – A variety of neurologic events have been described with the tropomyosin receptor kinase (TRK) inhibitors <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">larotrectinib</a> and <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">entrectinib</a>, including cognitive impairment, mood disorders, dizziness, and sleep disturbances. (See <a class="local">'NTRK inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ALK inhibitors</strong> – <a class="drug drug_general" data-topicid="119539" href="/z/d/drug information/119539.html" rel="external">Lorlatinib</a> is an anaplastic lymphoma kinase (ALK) inhibitor with a unique pattern of neurotoxicity that includes cognitive dysfunction, mood effects, speech disturbance, auditory hallucinations, and peripheral neuropathy. (See <a class="local">'Lorlatinib'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hauschild A, Gogas H, Tarhini A, et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008; 112:982.</a></li><li><a class="nounderline abstract_t">Caraceni A, Gangeri L, Martini C, et al. Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial. Cancer 1998; 83:482.</a></li><li><a class="nounderline abstract_t">Rohatiner AZ, Prior PF, Burton AC, et al. Central nervous system toxicity of interferon. Br J Cancer 1983; 47:419.</a></li><li><a class="nounderline abstract_t">Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41:672.</a></li><li><a class="nounderline abstract_t">Lerner DM, Stoudemire A, Rosenstein DL. Neuropsychiatric toxicity associated with cytokine therapies. Psychosomatics 1999; 40:428.</a></li><li><a class="nounderline abstract_t">Pavol MA, Meyers CA, Rexer JL, et al. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 1995; 45:947.</a></li><li><a class="nounderline abstract_t">Schachter J, Brenner B, Fenig E, et al. Toxicity of adjuvant high-dose interferon-alpha-2b in patients with cutaneous melanoma at high risk of recurrence. Oncol Rep 1999; 6:1389.</a></li><li><a class="nounderline abstract_t">Dickinson MD, Barr CD, Hiscock M, Meyers CA. Cognitive effects of pegylated interferon in individuals with primary brain tumors. J Neurooncol 2009; 95:231.</a></li><li><a class="nounderline abstract_t">Rutkove SB. An unusual axonal polyneuropathy induced by low-dose interferon alfa-2a. Arch Neurol 1997; 54:907.</a></li><li><a class="nounderline abstract_t">Bora I, Karli N, Bakar M, et al. Myasthenia gravis following IFN-alpha-2a treatment. Eur Neurol 1997; 38:68.</a></li><li><a class="nounderline abstract_t">Nishihori T, Abdo-Matkiwsky M, Fleishman SB, Blum RH. Severe action tremor related to interferon-alpha 2b therapy for malignant melanoma. Am J Clin Oncol 2005; 28:526.</a></li><li class="breakAll">Delattre J, Vega F, Chen Q. Neurologic complications of immunotherapy. In: Neurologic complications of cancer, Wiley RG (Ed), Marcel Dekker, New York 1995. p.267.</li><li><a class="nounderline abstract_t">Lipton JH, Khoroshko N, Golenkov A, et al. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia. Leuk Lymphoma 2007; 48:497.</a></li><li><a class="nounderline abstract_t">Denicoff KD, Rubinow DR, Papa MZ, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987; 107:293.</a></li><li><a class="nounderline abstract_t">Buzaid AC, Atkins M. Practical guidelines for the management of biochemotherapy-related toxicity in melanoma. Clin Cancer Res 2001; 7:2611.</a></li><li><a class="nounderline abstract_t">Petrella T, Quirt I, Verma S, et al. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 2007; 33:484.</a></li><li><a class="nounderline abstract_t">Bernard JT, Ameriso S, Kempf RA, et al. Transient focal neurologic deficits complicating interleukin-2 therapy. Neurology 1990; 40:154.</a></li><li><a class="nounderline abstract_t">Esteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer 1995; 76:1219.</a></li><li><a class="nounderline abstract_t">Fraenkel PG, Rutkove SB, Matheson JK, et al. Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer. J Immunother 2002; 25:373.</a></li><li><a class="nounderline abstract_t">Loh FL, Herskovitz S, Berger AR, Swerdlow ML. Brachial plexopathy associated with interleukin-2 therapy. Neurology 1992; 42:462.</a></li><li><a class="nounderline abstract_t">Barba D, Saris SC, Holder C, et al. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 1989; 70:175.</a></li><li><a class="nounderline abstract_t">Hayes RL, Koslow M, Hiesiger EM, et al. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 1995; 76:840.</a></li><li><a class="nounderline abstract_t">Hotton KM, Khorsand M, Hank JA, et al. A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: a case of fatal central nervous system thrombosis. Cancer 2000; 88:1892.</a></li><li><a class="nounderline abstract_t">Correale P, Campoccia G, Tsang KY, et al. Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trial. Eur J Cancer 2001; 37:892.</a></li><li><a class="nounderline abstract_t">Westermann J, Reich G, Kopp J, et al. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2001; 49:613.</a></li><li class="breakAll">Paleologos N. Complications of chemotherapy. In: Iatrogenic Neurology, Biller J (Ed), Butterworth-Heinemann, Boston 1998. p.439.</li><li><a class="nounderline abstract_t">Drory VE, Lev D, Groozman GB, et al. Neurotoxicity of isolated limb perfusion with tumor necrosis factor. J Neurol Sci 1998; 158:1.</a></li><li><a class="nounderline abstract_t">Piccinni C, Sacripanti C, Poluzzi E, et al. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. Eur J Clin Pharmacol 2010; 66:199.</a></li><li><a class="nounderline abstract_t">Sherman JH, Aregawi DG, Lai A, et al. Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology 2009; 73:1924.</a></li><li><a class="nounderline abstract_t">Pfeiffer P, Nielsen D, Yilmaz M, et al. Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol 2007; 46:697.</a></li><li><a class="nounderline abstract_t">Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18:904.</a></li><li><a class="nounderline abstract_t">Feinstein TM, Gibson MK, Argiris A. Cetuximab-induced aseptic meningitis. Ann Oncol 2009; 20:1609.</a></li><li><a class="nounderline abstract_t">Nagovskiy N, Agarwal M, Allerton J. Cetuximab-induced aseptic meningitis. J Thorac Oncol 2010; 5:751.</a></li><li><a class="nounderline abstract_t">Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363:1812.</a></li><li><a class="nounderline abstract_t">Shustov AR, Advani R, Brice P, et al. Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma (abstract 961). Blood 2010; 116:423.</a></li><li><a class="nounderline abstract_t">Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30:2190.</a></li><li><a class="nounderline abstract_t">Duvic M, Tetzlaff MT, Gangar P, et al. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol 2015; 33:3759.</a></li><li><a class="nounderline abstract_t">Kim YH, Tavallaee M, Sundram U, et al. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol 2015; 33:3750.</a></li><li><a class="nounderline abstract_t">Corbin ZA, Nguyen-Lin A, Li S, et al. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome. J Neurooncol 2017; 132:439.</a></li><li><a class="nounderline abstract_t">Straus DJ, Długosz-Danecka M, Connors JM, et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol 2021; 8:e410.</a></li><li><a class="nounderline abstract_t">Fargeot G, Dupel-Pottier C, Stephant M, et al. Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies. J Neurol Neurosurg Psychiatry 2020; 91:786.</a></li><li><a class="nounderline abstract_t">Rosenberg JE, O'Donnell PH, Balar AV, et al. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol 2019; 37:2592.</a></li><li class="breakAll">United States Prescribing Information for enfortumaab vedotin available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf (Accessed on December 19, 2019).</li><li><a class="nounderline abstract_t">Tilly H, Morschhauser F, Bartlett NL, et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol 2019; 20:998.</a></li><li><a class="nounderline abstract_t">Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol 2020; 38:155.</a></li><li><a class="nounderline abstract_t">Maloney DG, Grillo-López AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15:3266.</a></li><li><a class="nounderline abstract_t">Maloney DG, Press OW. Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies. Oncology (Williston Park) 1998; 12:63.</a></li><li><a class="nounderline abstract_t">Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18:317.</a></li><li><a class="nounderline abstract_t">Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834.</a></li><li><a class="nounderline abstract_t">Mavragani CP, Vlachoyiannopoulos PG, Kosmas N, et al. A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion. Rheumatology (Oxford) 2004; 43:1450.</a></li><li><a class="nounderline abstract_t">Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007; 25:1350.</a></li><li><a class="nounderline abstract_t">Bromberg JE, Doorduijn JK, Baars JW, et al. Acute painful lumbosacral paresthesia after intrathecal rituximab. J Neurol 2012; 259:559.</a></li><li class="breakAll">LABEL: TIVDAK- tisotumab vedotin injection, powder, for solution. DailyMed. National Library of Medicine. National Institutes of Health. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9fe3f32-4219-466e-acb9-3f609b4f4df1 (Accessed on December 19, 2022).</li><li><a class="nounderline abstract_t">Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96:1259.</a></li><li><a class="nounderline abstract_t">Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000; 18:1316.</a></li><li><a class="nounderline abstract_t">Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639.</a></li><li class="breakAll">FDA-approved prescribing information available online at http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf?et_cid=31141095&amp;et_rid=463638624&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2013%2f125427lbl.pdf (Accessed on February 25, 2013).</li><li><a class="nounderline abstract_t">Geraud A, Xu HP, Beuzeboc P, Kirova YM. Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer. J Neurooncol 2017; 131:69.</a></li><li><a class="nounderline abstract_t">Carlson JA, Nooruddin Z, Rusthoven C, et al. Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. Neuro Oncol 2014; 16:1006.</a></li><li class="breakAll">US Food and Drug Administration (FDA) Label for Larotrectinib https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf?et_cid=40674858&amp;et_rid=931330620&amp;linkid=https%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2018%2f211710s000lbl.pdf (Accessed on November 27, 2018).</li><li class="breakAll">US Prescribing information for entrectinib available online at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7c71b0c-2549-4495-86b6-c2807fa54908 (Accessed on February 12, 2020).</li><li><a class="nounderline abstract_t">Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol 2018; 19:1654.</a></li><li class="breakAll">United States Prescribing Information for avapritinib available online at: https://dailymed.nlm.nih.gov/dailymed/index.cfm.</li><li><a class="nounderline abstract_t">Chamilos G, Lionakis MS, Kontoyiannis DP. Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. Clin Infect Dis 2018; 66:140.</a></li><li><a class="nounderline abstract_t">Maschmeyer G, De Greef J, Mellinghoff SC, et al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia 2019; 33:844.</a></li><li><a class="nounderline abstract_t">Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell 2017; 31:833.</a></li><li class="breakAll">US prescribing information for ivosidenib, available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf (Accessed on August 16, 2018).</li><li class="breakAll">LABEL: XPOVIO- selinexor tablet, film coated. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6dd2682-75a6-4863-90a8-a3197f6f78a8 (Accessed on August 02, 2019).</li><li><a class="nounderline abstract_t">Brandi G, de Rosa F, Calzà L, et al. Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients? Liver Int 2013; 33:488.</a></li><li><a class="nounderline abstract_t">Marks AB, Gerard R, Fournier P, et al. Sorafenib-induced hepatic encephalopathy. Ann Pharmacother 2009; 43:2121.</a></li><li><a class="nounderline abstract_t">Arnaud L, Schartz NE, Bousquet G, et al. Transient sunitinib-induced coma in a patient with fibromyxoid sarcoma. J Clin Oncol 2008; 26:1569.</a></li><li><a class="nounderline abstract_t">Mannavola D, Coco P, Vannucchi G, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007; 92:3531.</a></li><li><a class="nounderline abstract_t">Lele AV, Clutter S, Price E, De Ruyter ML. Severe hypothyroidism presenting as myxedema coma in the postoperative period in a patient taking sunitinib: case report and review of literature. J Clin Anesth 2013; 25:47.</a></li><li><a class="nounderline abstract_t">Schiff D, Wen PY, van den Bent MJ. Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol 2009; 6:596.</a></li><li><a class="nounderline abstract_t">Martín G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 2007; 25:3559.</a></li><li><a class="nounderline abstract_t">Chen A, Agarwal N. Reversible posterior leucoencephalopathy syndrome associated with sunitinib. Intern Med J 2009; 39:341.</a></li><li><a class="nounderline abstract_t">Padhy BM, Shanmugam SP, Gupta YK, Goyal A. Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy. Br J Clin Pharmacol 2011; 71:777.</a></li><li><a class="nounderline abstract_t">Palma JA, Gomez-Ibañez A, Martin B, et al. Nonconvulsive status epilepticus related to posterior reversible leukoencephalopathy syndrome induced by cetuximab. Neurologist 2011; 17:273.</a></li><li><a class="nounderline abstract_t">Khan KH, Fenton A, Murtagh E, et al. Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature. Tumori 2012; 98:139e.</a></li><li><a class="nounderline abstract_t">Klein O, Ribas A, Chmielowski B, et al. Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma. J Clin Oncol 2013; 31:e215.</a></li></ol></div><div id="topicVersionRevision">Topic 2825 Version 55.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18236459" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9690541" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6830692" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Central nervous system toxicity of interferon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2027482" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Persistent neurotoxicity of systemically administered interferon-alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10479948" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Neuropsychiatric toxicity associated with cytokine therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7746412" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10523717" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Toxicity of adjuvant high-dose interferon-alpha-2b in patients with cutaneous melanoma at high risk of recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19484406" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cognitive effects of pegylated interferon in individuals with primary brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9236581" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : An unusual axonal polyneuropathy induced by low-dose interferon alfa-2a.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9252802" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Myasthenia gravis following IFN-alpha-2a treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16199995" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Severe action tremor related to interferon-alpha 2b therapy for malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16199995" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Severe action tremor related to interferon-alpha 2b therapy for malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17454589" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3497595" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11555571" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Practical guidelines for the management of biochemotherapy-related toxicity in melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17562357" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2296362" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Transient focal neurologic deficits complicating interleukin-2 therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630901" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12142560" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1310533" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Brachial plexopathy associated with interleukin-2 therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2643685" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Intratumoral LAK cell and interleukin-2 therapy of human gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8625188" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10760767" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: a case of fatal central nervous system thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11313178" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11225992" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11225992" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9667770" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Neurotoxicity of isolated limb perfusion with tumor necrosis factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19838692" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19949039" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Optic neuropathy in patients with glioblastoma receiving bevacizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17562448" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10673534" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19643807" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cetuximab-induced aseptic meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20421770" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cetuximab-induced aseptic meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21047225" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma (abstract 961)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22614995" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26261247" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26195720" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28271282" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34048680" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32327451" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31356140" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31356140" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31101489" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31693429" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9336364" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9830635" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10637245" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19264918" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15501998" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17312328" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21830092" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Acute painful lumbosacral paresthesia after intrathecal rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21830092" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Acute painful lumbosacral paresthesia after intrathecal rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10942366" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10715303" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561337" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561337" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27995546" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24497407" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24497407" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24497407" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30413378" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30413378" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29029010" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30700842" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28552327" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28552327" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28552327" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23402614" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19861429" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Sorafenib-induced hepatic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18349416" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Transient sunitinib-induced coma in a patient with fibromyxoid sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17595247" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23246982" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Severe hypothyroidism presenting as myxedema coma in the postoperative period in a patient taking sunitinib: case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19707193" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Neurological adverse effects caused by cytotoxic and targeted therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17687168" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Reversible posterior leukoencephalopathy syndrome induced by sunitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19382984" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Reversible posterior leucoencephalopathy syndrome associated with sunitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21480952" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21881470" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Nonconvulsive status epilepticus related to posterior reversible leukoencephalopathy syndrome induced by cetuximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235770" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23509307" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
